Insights

Innovative Pipeline Kodiak's focus on next-generation retinal therapeutics, including candidates like tarcocimab and KSI-501, presents opportunities for partnership in advanced ophthalmic drug development and commercial collaborations targeting high-prevalence retinal diseases.

Strong Financial Backing With substantial funding of $645 million and revenue between $10 million to $50 million, Kodiak is well-capitalized to accelerate its pipeline commercialization efforts, creating potential sales avenues for distribution and licensing of its innovative therapies.

Research & Collaboration Strategic partnerships, such as collaborations with Nona Biosciences and participation in major scientific forums, offer avenues for joint R&D projects and co-marketing opportunities with a focus on advanced antibody therapies and ophthalmic innovations.

Market Engagement Active participation in global scientific conferences and industry events indicates Kodiak's openness to strategic partnerships and market expansion, making it a promising target for engagement with stakeholders involved in ophthalmology and biotech commercialization.

Technology Edge Kodiak's proprietary ABC Platform™ and its focus on embedding small molecules and designing multifunctional bioconjugates demonstrate technological leadership, opening opportunities for sales of platform licensing, collaborative research, and early-access to cutting-edge ophthalmic biologics.

Similar companies to Kodiak Sciences Inc.

Kodiak Sciences Inc. Tech Stack

Kodiak Sciences Inc. uses 8 technology products and services including Akamai, Open Graph, Modernizr, and more. Explore Kodiak Sciences Inc.'s tech stack below.

  • Akamai
    Content Delivery Network
  • Open Graph
    Content Management System
  • Modernizr
    Javascript Libraries
  • HSTS
    Security
  • Akamai Bot Manager
    Security
  • Drupal Multisite
    Web Hosting
  • Nginx
    Web Servers
  • prettyPhoto
    Web Tools And Plugins

Media & News

Kodiak Sciences Inc.'s Email Address Formats

Kodiak Sciences Inc. uses at least 1 format(s):
Kodiak Sciences Inc. Email FormatsExamplePercentage
FLast@kodiak.comJDoe@kodiak.com
86%
Last@kodiak.comDoe@kodiak.com
9%
First.Last@kodiak.comJohn.Doe@kodiak.com
4%
FMLast@kodiak.comJMDoe@kodiak.com
1%

Frequently Asked Questions

Where is Kodiak Sciences Inc.'s headquarters located?

Minus sign iconPlus sign icon
Kodiak Sciences Inc.'s main headquarters is located at 1250 Page Mill Rd, Palo Alto, California 94304, US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Kodiak Sciences Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Kodiak Sciences Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kodiak Sciences Inc.'s stock symbol?

Minus sign iconPlus sign icon
Kodiak Sciences Inc. is a publicly traded company; the company's stock symbol is KOD.

What is Kodiak Sciences Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Kodiak Sciences Inc.'s official website is kodiak.com and has social profiles on LinkedInCrunchbase.

What is Kodiak Sciences Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Kodiak Sciences Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Kodiak Sciences Inc. have currently?

Minus sign iconPlus sign icon
As of October 2025, Kodiak Sciences Inc. has approximately 123 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Scientific Officer: D. C.Vice President Of Clinical Operations: D. B.Co-Founder And Chief Executive Officer: S. C.. Explore Kodiak Sciences Inc.'s employee directory with LeadIQ.

What industry does Kodiak Sciences Inc. belong to?

Minus sign iconPlus sign icon
Kodiak Sciences Inc. operates in the Biotechnology Research industry.

What technology does Kodiak Sciences Inc. use?

Minus sign iconPlus sign icon
Kodiak Sciences Inc.'s tech stack includes AkamaiOpen GraphModernizrHSTSAkamai Bot ManagerDrupal MultisiteNginxprettyPhoto.

What is Kodiak Sciences Inc.'s email format?

Minus sign iconPlus sign icon
Kodiak Sciences Inc.'s email format typically follows the pattern of FLast@kodiak.com. Find more Kodiak Sciences Inc. email formats with LeadIQ.

How much funding has Kodiak Sciences Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2025, Kodiak Sciences Inc. has raised $645M in funding. The last funding round occurred on Nov 17, 2020 for $645M.

When was Kodiak Sciences Inc. founded?

Minus sign iconPlus sign icon
Kodiak Sciences Inc. was founded in 2009.
Kodiak Sciences Inc.

Kodiak Sciences Inc.

Biotechnology ResearchUnited States51-200 Employees

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein for the treatment of retinal inflammatory diseases. We are advancing our platform technology to embed small molecules and other active pharmaceutical ingredients for multifactorial diseases.

WORKING AT KODIAK 
We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you!

Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.

Section iconCompany Overview

Headquarters
1250 Page Mill Rd, Palo Alto, California 94304, US
Phone number
Website
kodiak.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
KOD
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $645M

    Kodiak Sciences Inc. has raised a total of $645M of funding over 5 rounds. Their latest funding round was raised on Nov 17, 2020 in the amount of $645M.

  • $25M$50M

    Kodiak Sciences Inc.'s revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $645M

    Kodiak Sciences Inc. has raised a total of $645M of funding over 5 rounds. Their latest funding round was raised on Nov 17, 2020 in the amount of $645M.

  • $25M$50M

    Kodiak Sciences Inc.'s revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.